16 completed, 1 not yet recruiting. 7 Phase 2, 4 Phase 3, 3 Phase 1, 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Sitagliptin 100 mg: new trials by email Literature Review of Sitagliptin 100 mg trials Research Report on Sitagliptin 100 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg - Diabetes Mellitus, Type 2, Hyperglycemia | Phase 4 | Not yet recruiting | Yonsei University | 100 | 2025-09-01 | 2025-08-07 |
| DPP4-Inhibitors and Bone Metabolism in Diabetes Sitagliptin 100 mg, Placebo Tablets - Osteoporosis, Bone Loss, Postmenopausal | Phase 3 | Completed | Azienda Policlinico Umberto I | 132 | 2019-09-24 | 2025-01-13 |
| Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients Sitagliptin 100 mg, Placebo - Pharmacological Action | Phase 2 | Completed | Profil Institut für Stoffwechselforschung GmbH | 20 | 2018-03-21 | 2021-02-21 |
| An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Janssen Research & Development, LLC | 64 | 2017-10-27 | 2019-11-29 |
| 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin Sitagliptin 100 mg, DS-8500a 25mg, Placebo Tablet - Type 2 Diabetes Mellitus | Phase 2 | Completed | Daiichi Sankyo | 298 | 2016-01-01 | 2019-02-25 |
| Add Glucokinase Activator to Target A1c TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg - Diabetes Mellitus, Type 2 | Phase 2 | Completed | vTv Therapeutics | 190 | 2015-03-01 | 2017-02-10 |
| Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) Matching Placebo to Ertugliflozin 5 mg, Matching Placebo to Ertugliflozin 10 mg, Matching Placebo to sitagliptin 100 mg - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1233 | 2014-04-22 | 2018-09-12 |
| A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142) Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg - Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 22 | 2012-06-21 | 2017-05-30 |
| Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus Placebo, 150 mg PF-04991532, 450 mg PF-04991532 - Diabetes, Type 2 | Phase 2 | Completed | Pfizer | 266 | 2011-06-01 | 2013-08-06 |
| Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes Placebo, 25 mg PF-04991532, 75 mg PF-04991532 - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Pfizer | 301 | 2011-06-01 | 2013-04-23 |
| Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121) Sitagliptin 50 mg, Metformin 500 mg, Sitagliptin 100 mg - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 744 | 2010-11-15 | 2017-05-23 |
| The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial) Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Janssen Research & Development, LLC | 756 | 2010-07-01 | 2015-01-15 |
| Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) Placebo to Ertugliflozin, Ertugliflozin 1 mg, Ertugliflozin 5 mg - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Merck Sharp & Dohme LLC | 375 | 2010-02-24 | 2018-09-13 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 18 | 2009-12-01 | 2013-09-04 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 25 | 2009-04-01 | 2014-05-22 |
| Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome Sitagliptin 100 mg, Prednisolone 30 mg, Sitagliptin-placebo - Diabetes Mellitus, Steroid Diabetes | Not applicable | Completed | Amsterdam UMC, location VUmc | 82 | 2008-10-01 | 2012-07-02 |
| Sitagliptin in the Elderly Sitagliptin 100 mg - Type 2 Diabetes | Phase 2 | Completed | University of British Columbia | 12 | 2006-11-01 | 2018-01-18 |
Diabetes Mellitus, Type 2 (15) · Insulin Resistance (3) · Hyperglycemia (2) · Diabetes Mellitus (1) · Osteoporosis (1) · Osteoporosis, Postmenopausal (1)
Merck Sharp & Dohme LLC (4) · Janssen Research & Development, LLC (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Pfizer (2) · Amsterdam UMC, location VUmc (1) · Azienda Policlinico Umberto I (1) · Daiichi Sankyo (1) · Profil Institut für Stoffwechselforschung GmbH (1) · University of British Columbia (1) · Yonsei University (1) · vTv Therapeutics (1)
United States (7) · Canada (5) · Mexico (3) · South Korea (3) · Germany (2) · Hungary (2) · Netherlands (2) · Slovakia (2) · Taiwan (2) · Austria (1) · Belgium (1) · Brazil (1) · Denmark (1) · France (1) · India (1)
Carmen Valcarce, Ph.D. (1) · Christoph Kapitza, MD (1) · Graydon Meneilly, MD (1) · Michaela Diamant, Md PhD (1)
PMID 34213819, PMID 21668924, PMID 23178932, PMID 23564919, PMID 24163113, PMID 24297090, PMID 24585202, PMID 25754396, PMID 25795432, PMID 26579834, PMID 26580237, PMID 27181998, PMID 27391951, PMID 27977934, PMID 29266675, PMID 29313267, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 32700393, PMID 41088165
2009 (1), 2018 (1)